◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

NervGen Pharma Corp.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item FY 2024Dec 31, 2024 FY 2023Dec 31, 2023 FY 2022Dec 31, 2022 FY 2021Dec 31, 2021
Total Revenue 0.00 0.00 0.00 0.00
Operating Revenue 0.00 0.00 0.00 0.00
Selling General And Administration 9.2M 9.6M 6.3M 5.9M
General And Administrative Expense 9.2M 9.6M 6.3M 5.9M
Research And Development 15.7M 8.0M 16.6M 6.9M
Depreciation And Amortization In Income Statement 28,003 98,572 73,365 2,054
Operating Expense 24.9M 17.8M 23.0M 12.8M
Operating Income -24.9M -17.8M -23.0M -12.8M
EBIT -24.9M -17.8M -20.2M -12.7M
Interest Expense -- 0.00 514,599 0.00
Interest Expense Non Operating -- 0.00 514,599 0.00
Interest Income 812,617 550,074 201,396 29,417
Interest Income Non Operating 812,617 550,074 201,396 29,417
Net Interest Income 812,617 550,074 -313,203 29,417
Other Income Expense 113,483 -5.2M 2.6M 55,229
Gain On Sale Of Security 113,483 -5.2M 2.6M 55,229
Pretax Income -24.0M -22.4M -20.7M -12.7M
Tax Effect Of Unusual Items 0.00 0.00 0.00 0.00
Net Income From Continuing And Discontinued Operation -24.0M -22.4M -20.7M -12.7M
Net Income From Continuing Operation Net Minority Interest -24.0M -22.4M -20.7M -12.7M
Net Income Including Noncontrolling Interests -24.0M -22.4M -20.7M -12.7M
Net Income Common Stockholders -24.0M -22.4M -20.7M -12.7M
Net Income -24.0M -22.4M -20.7M -12.7M
EBITDA -24.8M -17.6M -20.1M -12.7M
Normalized EBITDA -25.0M -12.5M -22.7M -12.7M
Reconciled Depreciation 83,798 145,002 115,114 42,626
Basic EPS -0.36 -0.38 -0.39 -0.32
Diluted EPS -0.36 -0.38 -0.39 -0.32
Basic Average Shares 67.3M 59.3M 52.6M 39.3M
Diluted Average Shares 67.3M 59.3M 52.6M 39.3M
Total Unusual Items 113,483 -5.2M 2.6M 55,229
Total Unusual Items Excluding Goodwill 113,483 -5.2M 2.6M 55,229
Tax Rate For Calcs 0.00 0.00 0.00 0.00
Normalized Income -24.1M -17.2M -23.3M -12.8M
Depreciation Amortization Depletion Income Statement 28,003 98,572 73,365 2,054
Depreciation Income Statement 28,003 98,572 73,365 2,054
Diluted NI Availto Com Stockholders -24.0M -22.4M -20.7M -12.7M
Net Income Continuous Operations -24.0M -22.4M -20.7M -12.7M
Net Non Operating Interest Income Expense 812,617 550,074 -313,203 29,417
Other Gand A 2.6M 2.9M 3.1M 1.7M
Salaries And Wages 6.5M 6.8M 3.3M 4.3M
Total Expenses 24.9M 17.8M 23.0M 12.8M
Total Other Finance Cost -- -- -- 1.4M
Line Item FY 2024Dec 31, 2024 FY 2023Dec 31, 2023 FY 2022Dec 31, 2022 FY 2021Dec 31, 2021
Cash And Cash Equivalents 17.3M 11.7M 22.5M 16.9M
Cash Cash Equivalents And Short Term Investments 17.4M 11.7M 22.5M 16.9M
Cash Financial -- -- 22.5M 16.9M
Other Short Term Investments 97,234 0.00 -- --
Accounts Receivable -- 250,209 27,027 64,002
Receivables 415,301 250,209 27,027 64,002
Prepaid Assets 716,951 589,403 669,908 427,577
Other Current Assets 105,664 16,330 -- --
Current Assets 19.0M 12.5M 23.1M 17.4M
Gross PPE 0.00 199,782 295,280 --
Net PPE 0.00 199,782 295,280 2,691
Goodwill And Other Intangible Assets 464,958 520,753 431,403 473,152
Other Intangible Assets 464,958 520,753 431,403 473,152
Investments And Advances 8,369 0.00 -- --
Other Investments 8,369 0.00 -- --
Total Non Current Assets 473,327 720,535 726,683 475,843
Total Assets 19.5M 13.2M 23.9M 17.9M
Current Debt And Capital Lease Obligation 97,234 91,586 86,265 --
Accounts Payable -- 3.3M 2.0M 352,546
Payables 33,439 3.3M 2.5M 626,609
Payables And Accrued Expenses 3.8M 2.6M 3.4M 1.1M
Current Accrued Expenses 3.7M 2.6M 892,136 451,471
Other Current Liabilities 11.9M 11.8M 6.7M --
Current Liabilities 16.9M 15.1M 10.2M 1.1M
Long Term Debt And Capital Lease Obligation 8,369 105,604 197,190 0.00
Long Term Capital Lease Obligation 8,369 105,604 197,190 0.00
Total Non Current Liabilities Net Minority Interest 8,369 105,604 197,190 0.00
Total Liabilities Net Minority Interest 16.9M 15.2M 10.4M 1.1M
Common Stock 81.1M 58.9M 57.4M 42.4M
Capital Stock 81.1M 58.9M 57.4M 42.4M
Retained Earnings -102.2M -78.2M -55.8M -35.0M
Gains Losses Not Affecting Retained Earnings 23.6M 17.2M 11.8M 9.5M
Common Stock Equity 2.6M -2.0M 13.5M 16.8M
Stockholders Equity 2.6M -2.0M 13.5M 16.8M
Total Equity Gross Minority Interest 2.6M -2.0M 13.5M 16.8M
Total Capitalization 2.6M -2.0M 13.5M 16.8M
Net Tangible Assets 2.1M -2.5M 13.0M 16.3M
Tangible Book Value 2.1M -2.5M 13.0M 16.3M
Working Capital 2.1M -2.6M 12.9M 16.3M
Invested Capital 2.6M -2.0M 13.5M 16.8M
Total Debt 105,603 197,190 283,455 0.00
Share Issued 70.3M 59.6M 58.8M 46.2M
Ordinary Shares Number 70.3M 59.6M 58.8M 46.2M
Capital Lease Obligations 105,603 197,190 283,455 0.00
Current Capital Lease Obligation 97,234 91,586 86,265 0.00
Current Deferred Assets 410,257 0.00 -- --
Dueto Related Parties Current -- 438,584 504,346 274,063
Other Payable 33,439 -- -- --
Other Properties -- 199,782 295,280 --
Other Receivables 270,645 249,879 -- --
Pensionand Other Post Retirement Benefit Plans Current 1.2M 710,392 -- --
Taxes Receivable 144,656 330.00 -- --
Line Item FY 2024Dec 31, 2024 FY 2023Dec 31, 2023 FY 2022Dec 31, 2022 FY 2021Dec 31, 2021
Operating Cash Flow -16.8M -11.3M -17.8M -8.3M
Cash Flow From Continuing Operating Activities -16.8M -11.3M -17.8M -8.3M
Depreciation And Amortization 83,798 145,002 115,114 42,626
Depreciation Amortization Depletion 83,798 145,002 115,114 42,626
Stock Based Compensation 5.8M 6.0M 2.8M 4.0M
Change In Working Capital 838,556 -240,348 2.1M 430,499
Changes In Account Receivables -165,092 -223,182 36,975 -1,408
Change In Receivables -165,092 -223,182 36,975 -1,408
Change In Payables And Accrued Expense 1.2M -74,488 2.3M 318,734
Change In Payable -- -- 2.3M 318,734
Other Non Cash Items 9,790 14,661 528,900 --
Capital Expenditure -- -141,403 -21,105 -45,085
Purchase Of PPE 0.00 -5,623 -21,105 -2,749
Net PPE Purchase And Sale 0.00 -3,074 -21,105 -2,749
Investing Cash Flow 58,874 -138,854 -21,105 -45,085
Cash Flow From Continuing Investing Activities 58,874 -138,854 -21,105 -45,085
Repayment Of Debt -100,926 -100,926 -75,695 0.00
Net Issuance Payments Of Debt -100,926 -100,926 -75,695 0.00
Issuance Of Capital Stock 23.0M 0.00 19.8M 18.9M
Net Common Stock Issuance 23.0M 0.00 19.8M 18.9M
Financing Cash Flow 22.7M 766,285 22.6M 19.6M
Cash Flow From Continuing Financing Activities 22.7M 766,285 22.6M 19.6M
Effect Of Exchange Rate Changes -305,006 -123,892 686,575 31,377
Changes In Cash 5.9M -10.7M 4.8M 11.3M
Beginning Cash Position 11.7M 22.5M 16.9M 5.6M
End Cash Position 17.3M 11.7M 22.5M 16.9M
Free Cash Flow -16.8M -11.4M -17.8M -8.3M
Interest Paid Supplemental Data 0.00 0.00 0.00 0.00
Amortization Cash Flow 55,795 46,430 41,749 40,572
Amortization Of Intangibles 55,795 46,430 41,749 40,572
Change In Account Payable -- -- 2.3M 318,734
Change In Prepaid Assets -223,735 57,322 -242,331 113,173
Common Stock Issuance 23.0M 0.00 19.8M 18.9M
Depreciation 28,003 98,572 73,365 2,054
Gain Loss On Investment Securities 135,959 5.0M -1.9M --
Gain Loss On Sale Of PPE 6,851 0.00 -- --
Long Term Debt Payments -100,926 -100,926 -75,695 0.00
Net Foreign Currency Exchange Gain Loss 294,337 128,043 -686,575 -31,377
Net Income From Continuing Operations -24.0M -22.4M -20.7M -12.7M
Net Intangibles Purchase And Sale 58,874 -135,780 0.00 -42,336
Net Long Term Debt Issuance -100,926 -100,926 -75,695 0.00
Net Other Financing Charges -1.6M -- -129,042 -1.7M
Operating Gains Losses 437,147 5.1M -2.6M -31,377
Proceeds From Stock Option Exercised 1.4M 867,211 3.1M 2.4M
Purchase Of Intangibles 0.00 -135,780 0.00 -42,336
Sale Of Intangibles 58,874 0.00 -- --
Sale Of PPE 0.00 2,549 0.00 --
NEWS
Loading news...
TRENDING
Loading...